{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:57:32Z","timestamp":1769612252758,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01959-7","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:19:36Z","timestamp":1767417576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-TNF-targeted drugs in rheumatic diseasescombined with latent tuberculosis infection"],"prefix":"10.1007","volume":"26","author":[{"given":"Zhicong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Liuyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hequn","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1959_CR1","doi-asserted-by":"publisher","unstructured":"Miltinien\u0117 D, Deresevic\u02c7ien\u0117 G, Nakc\u02c7erien\u0117 B et al. Incidence of tuberculosis in inflammatory rheumatic diseases: results from a Lithuanian retrospective cohort studymedicina (Kaunas), 2020, 56(8):392. https:\/\/doi.org\/10.3390\/medicina56080392","DOI":"10.3390\/medicina56080392"},{"issue":"2","key":"1959_CR2","doi-asserted-by":"publisher","first-page":"e034356","DOI":"10.1136\/bmjopen-2019-034356","volume":"10","author":"Z Rotar","year":"2020","unstructured":"Rotar Z, Svetina P, Tomsic M, et al. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis,ankylosing spondylitis and psoriatic arthritis in slovenia:a cohort StudyBMJ. Open. 2020;10(2):e034356. https:\/\/doi.org\/10.1136\/bmjopen-2019-034356.","journal-title":"Open"},{"key":"1959_CR3","doi-asserted-by":"crossref","unstructured":"Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, Mason J, Sattar,N.,McMurray JJV. &Cambridge,G.2023.Incidence,prevalence,and co-occurrence of autoimmune disorders over time and by age,sex,and socioeconomic statusa population-based cohort study of 22 million individuals in the UK.The Lancet,40110391,1878\u201390.","DOI":"10.1016\/S0140-6736(23)00457-9"},{"issue":"Suppl 2","key":"1959_CR4","doi-asserted-by":"publisher","first-page":"ii37","DOI":"10.1136\/ard.62.suppl_2.ii37","volume":"62","author":"S Ehlers","year":"2003","unstructured":"Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis. 2003;62(Suppl 2):ii37\u201342. https:\/\/doi.org\/10.1136\/ard.62.suppl_2.ii37.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1959_CR5","doi-asserted-by":"publisher","first-page":"e20190023","DOI":"10.1590\/1806-3713\/e20190023","volume":"45","author":"C Anton","year":"2019","unstructured":"Anton C, Machado FD, Ramirez JMA, et al. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol. 2019;45(2):e20190023. https:\/\/doi.org\/10.1590\/1806-3713\/e20190023.","journal-title":"J Bras Pneumol"},{"issue":"7","key":"1959_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/1756-185X.12375","volume":"17","author":"R Scrivo","year":"2014","unstructured":"Scrivo R, Armignacco O. Tuberculosis risk and anti-tumour necrosis factoragents in rheumatoid arthritis: a critical appraisal of National registry data. Int J Rheum Dis. 2014;17(7):716\u201324. https:\/\/doi.org\/10.1111\/1756-185X.12375.","journal-title":"Int J Rheum Dis"},{"issue":"15","key":"1959_CR7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098\u2013104.","journal-title":"N Engl J Med"},{"issue":"1","key":"1959_CR8","first-page":"123","volume":"65","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Curtis JR, Chen L, et al. Incidence of tuberculosis amongrheumatoid arthritis patients treated with abatacept, rituximab, or tocilizumab: a retrospective cohort study. Arthritis Rheum. 2013;65(1):123\u201332.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1959_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1\u201326.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9820","key":"1959_CR10","first-page":"1073","volume":"379","author":"EC Keystone","year":"2012","unstructured":"Keystone EC, Kavanaugh A, Genovese MC, et al. Oral Janus kinase inhibitor Tofacitinib in the treatment of rheumatoid arthritis: a randomised, placebo-controlled, phase II trial. Lancet. 2012;379(9820):1073\u201381.","journal-title":"Lancet"},{"key":"1959_CR11","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018."},{"issue":"2","key":"1959_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/annrheumdis-2019-216128","volume":"79","author":"C Pettipher","year":"2020","unstructured":"Pettipher C, Benitha R. Tuberculosis in biologic users for rheumatic diseases: results from the South African biologics registry (SABIO). Ann Rheum Dis. 2020;79(2):292\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216128.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1959_CR13","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/1756-185X.13261","volume":"21","author":"AN Malaviya","year":"2018","unstructured":"Malaviya AN, Aggarwal VK, Rawat R, et al. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: the importance of Mantoux and Quantiferon-TB gold tests. Int J Rheum Dis. 2018;21(8):1563\u201371. https:\/\/doi.org\/10.1111\/1756-185X.13261.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"1959_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-016-3462-z","volume":"36","author":"G Cuomo","year":"2017","unstructured":"Cuomo G, D\u2019Abrosca V, Iacono D, et al. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol. 2017;36(2):457\u201361. https:\/\/doi.org\/10.1007\/s10067-016-3462-z.","journal-title":"Clin Rheumatol"},{"key":"1959_CR15","unstructured":"World Health Organization. 2018.Global tuberculosis report 2018.World Health Organization."},{"issue":"2","key":"1959_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/23744235.2019.1682187","volume":"52","author":"W Long","year":"2020","unstructured":"Long W, Cai F, Wang X, et al. High risk of activation of latent tuberculosis infection in rheumatic disease patients. Infect Dis (Lond). 2020;52(2):80\u20136. https:\/\/doi.org\/10.1080\/23744235.2019.1682187.","journal-title":"Infect Dis (Lond)"},{"issue":"6","key":"1959_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00296-020-04583-8","volume":"40","author":"TT Chung","year":"2020","unstructured":"Chung TT, Ko HJ, Lau CS, et al. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int. 2020;40(6):983\u201390. https:\/\/doi.org\/10.1007\/s00296-020-04583-8.","journal-title":"Rheumatol Int"},{"key":"1959_CR18","doi-asserted-by":"publisher","unstructured":"Ciang NC, Chan SCW, Lau CS et al. Risk of tuberculosis in patients with spondyloarthritis:data from a centralized electronic database in Hong Kong.BMC musculoskelet Disord, 2020, 21(1):832. https:\/\/doi.org\/10.1186\/s12891-020-03855-5","DOI":"10.1186\/s12891-020-03855-5"},{"key":"1959_CR19","doi-asserted-by":"publisher","first-page":"1759720X2093011","DOI":"10.1177\/1759720X20930116","volume":"12","author":"G Evangelatos","year":"2020","unstructured":"Evangelatos G, Koulouri V, Iliopoulos A, et al. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020;12:1759720X20930116. https:\/\/doi.org\/10.1177\/1759720X20930116.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"1959_CR20","first-page":"344","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. IL-6 as a keystone cytokine in health and disease. Nat Rev Immunol. 2018;18(5):344\u201357.","journal-title":"Nat Rev Immunol"},{"key":"1959_CR21","first-page":"1","volume":"28","author":"T Kishimoto","year":"2010","unstructured":"Kishimoto T. Interleukin-6: from basic science to medicine\u201440 years in the making. Annu Rev Immunol. 2010;28:1\u201321.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"1959_CR22","first-page":"1534","volume":"43","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Kanakura Y. Humanized anti-interleukin-6 receptor antibody, tocilizumab, in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2004;43(12):1534\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1959_CR23","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","volume":"10","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC. Tocilizumab in combination with methotrexate in patients with rheumatoid arthritis: a 24-week randomized controlled trial. Arthritis Res Ther. 2008;10(2):R45.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1959_CR24","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/ar3244","volume":"13","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Lovell DJ. Long-term safety and efficacy of Tocilizumab in juvenile idiopathic arthritis: a multicenter, open-label, phase III study. Arthritis Res Ther. 2011;13(1):R20.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1959_CR25","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar3279","volume":"13","author":"JA Singh","year":"2011","unstructured":"Singh JA, Furst DE. Safety of biologics in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Res Ther. 2011;13(2):R43.","journal-title":"Arthritis Res Ther"},{"key":"1959_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3109\/s10165-009-0243-4","volume":"20","author":"A Ogata","year":"2010","unstructured":"Ogata A, Mori M, Hashimoto S, et al. Minimal influence of Tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol. 2010;20:130\u20133.","journal-title":"Mod Rheumatol"},{"key":"1959_CR27","doi-asserted-by":"crossref","unstructured":"Campbell C, Andersson MI, Ansari MA, Moswela O, Misbah SA, &Matthews PC. 2021.Risk of reactivation of hepatitis B virushbvand tuberculosistband complications of hepatitis C virushcvfollowing Tocilizumab therapya systematic review to inform risk assessment in the COVID-19 Era.Frontiers in Medicine,8,706482.","DOI":"10.3389\/fmed.2021.706482"},{"key":"1959_CR28","doi-asserted-by":"crossref","unstructured":"Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm. 2017; 2017:8909834.","DOI":"10.1155\/2017\/8909834"},{"issue":"10080","key":"1959_CR29","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)30142-4","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Sieper J. Psoriatic arthritis. Lancet. 2017;389(10080):2338\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(17)30142-4.","journal-title":"Lancet"},{"key":"1959_CR30","doi-asserted-by":"publisher","unstructured":"Yu CL, Yang CH, Chi CC. Drug survival of biologics in treating ankylosing spondylitis:a systematic review and Meta-analysis of Real-World Evidence.BioDrugs, 2020, 34(5):669\u201379. https:\/\/doi.org\/10.1007\/s40259-020-00442-x","DOI":"10.1007\/s40259-020-00442-x"},{"issue":"2","key":"1959_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","volume":"16","author":"YM Chiu","year":"2020","unstructured":"Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis:non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207\u201328. https:\/\/doi.org\/10.1080\/1744666X.2019.1705785.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"1959_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/rheumatology\/kew279","volume":"56","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, et al. Safety and tolerability of Secukinumab in patients with ankylosing: pooled analysis of phase 3 MEASURE 1, 2, and 3 studies. Rheumatology (Oxford). 2017;56(3):438\u201345. https:\/\/doi.org\/10.1093\/rheumatology\/kew279.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1959_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/rheumatology\/kew280","volume":"56","author":"K Reich","year":"2017","unstructured":"Reich K, et al. Safety and tolerability of Secukinumab in patients with psoriatic: pooled analysis of phase 3 FUTURE 1, 2, and 3 studies. Rheumatology (Oxford). 2017;56(3):446\u201353. https:\/\/doi.org\/10.1093\/rheumatology\/kew280.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1959_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski BE, Baddley JW, Deodhar AA, et al. Association of Secukinumab treatment with tuberculosis reactivation in patients with Psoriasis,Psoriatic Arthritis,or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3257.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1959_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"Cantini F, Blandizzi C, Niccoli L, et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus kinases. Expert Opin Drug Saf. 2020;19(7):861\u201372. https:\/\/doi.org\/10.1080\/14740338.2020.1774550.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"1959_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","volume":"18","author":"F Cantini","year":"2019","unstructured":"Cantini F, Niccoli L, Capone A, et al. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019;18(5):415\u201325. https:\/\/doi.org\/10.1080\/14740338.2019.1612872.","journal-title":"Expert Opin Drug Saf"},{"key":"1959_CR37","doi-asserted-by":"publisher","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate to severe psoriasis through 5 years of treatment(SCULPTURE extension Study) [J]. J Eur Acad Dermatol Venereol. 2018;1507\u201314. https:\/\/doi.org\/10.1111\/jdv.14878.3.","DOI":"10.1111\/jdv.14878.3"},{"key":"1959_CR38","doi-asserted-by":"publisher","unstructured":"Kamm\u00fcller M, Tsai TF, Griffiths CE et al. Inhibition of IL-17A by secukinumab shows no evidence of increased tuberculosis infections [J]. Clin Transl Immunology, 2017,6Mycobacterium (8):e152. https:\/\/doi.org\/10.1038\/cti.2017.34","DOI":"10.1038\/cti.2017.34"},{"key":"1959_CR39","doi-asserted-by":"crossref","unstructured":"Galluzzo M, Talamonti M, De Simone C et al. Secukinumab in moderate to severe plaque psoriasis: a multi \u2043 center,Expert Opin biol Ther, 2018, 18 retrospective, real life study up to 52 weeks observation(7): 727\u201335. doi: 10.1080\/ [J]. 14712598.2018.1481503.","DOI":"10.1080\/14712598.2018.1481503"},{"key":"1959_CR40","doi-asserted-by":"publisher","first-page":"36923","DOI":"10.1038\/srep36923","volume":"6","author":"N Segueni","year":"2016","unstructured":"Segueni N, Tritto E, Bourigault ML, et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti IL-17A or IL-17F antibodies, in contrast to TNF\u03b1 neutralization [J]. Sci Rep. 2016;6:36923. https:\/\/doi.org\/10.1038\/srep36923.","journal-title":"Sci Rep"},{"issue":"1","key":"1959_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, et al. Long-term safety and efficacy of Ixekizumab in patients with ankylosing spondylitis: 5-year results from the COAST-V and COAST-W studies. Ann Rheum Dis. 2020;79(1):88\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1959_CR42","first-page":"4567","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Tuberculosis risk assessment in patients with rheumatic diseases treated with Ixekizumab in a high tuberculosis prevalence region. Clin Rheumatol. 2021;40(12):4567\u201373.","journal-title":"Clin Rheumatol"},{"key":"1959_CR43","doi-asserted-by":"publisher","unstructured":"Torrado E, Cooper AM, IL\u204317 and Th17 cells in tuberculosis [J]. Cytokine Growth Factor Rev. 2010;21(6):455\u201362. https:\/\/doi.org\/10.1016\/j.cytogfr.2010.10.004.","DOI":"10.1016\/j.cytogfr.2010.10.004"},{"issue":"7","key":"1959_CR44","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jdv.16254","volume":"34","author":"E Fowler","year":"2020","unstructured":"Fowler E, Ghamrawi RI, Ghiam N, et al. Risk of tuberculosis reactivation during interleukin\u204317 inhibitor therapy for psoriasis: a systematic review [J]. J Eur Acad Dermatol Venereol. 2020;34(7):1449\u201356. https:\/\/doi.org\/10.1111\/jdv.16254.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1959_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjd.17604","volume":"181","author":"R Romiti","year":"2019","unstructured":"Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis [J]. Br J Dermatol. 2019;181(1):202\u20133. https:\/\/doi.org\/10.1111\/bjd.17604.","journal-title":"Br J Dermatol"},{"key":"1959_CR46","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Riedl E, Winkler S et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis [J]. J Am Acad Dermatol, 2020, 83(5): 1436 \u2043 1439. 10.1016\/j. jaad. 2020.06.012.","DOI":"10.1016\/j.jaad.2020.06.012"},{"issue":"10","key":"1959_CR47","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.3390\/cells9102184","volume":"9","author":"DM Floss","year":"2020","unstructured":"Floss DM, Moll JM, Scheller J. IL\u204312 and IL\u204323\u2043close relatives with structural homologies but distinct immunological functions [J]. Cells. 2020;9(10):2184. https:\/\/doi.org\/10.3390\/cells9102184.","journal-title":"Cells"},{"key":"1959_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3389\/fimmu.2018.00709","volume":"9","author":"N Gupta","year":"2018","unstructured":"Gupta N, Kumar R, Agrawal B. New players in immunity to tuberculosis: the host microbiome, lung epithelium, and innate immune cells [J]. Front Immunol. 2018;9:709. https:\/\/doi.org\/10.3389\/fimmu.2018.00709.","journal-title":"Front Immunol"},{"issue":"6","key":"1959_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","volume":"16","author":"A L\u00f3pez-Ferrer","year":"2017","unstructured":"L\u00f3pez-Ferrer A, Laiz A, Puig L. The safety of ustekinumab for the treatment of psoriatic arthritis [J]. Expert Opin Drug Saf. 2017;16(6):733\u201342. https:\/\/doi.org\/10.1080\/14740338.2017.1323864.","journal-title":"Expert Opin Drug Saf"},{"key":"1959_CR50","doi-asserted-by":"publisher","unstructured":"Jung SW, Lim SH, Jeon JJ et al. Comparison of the efficacy and safety of biologics(secukinumab, ustekinumab, and guselkumab)for the treatment of moderate\u2043to\u2043severe psoriasis: real\u2043world data from a single Korean center [J]. Biomedicines, 2022,10\u0f085\u0f09:1058.https:\/\/doi.org\/10.3390\/biomedicines10051058","DOI":"10.3390\/biomedicines10051058"},{"key":"1959_CR51","doi-asserted-by":"publisher","unstructured":"Kaneko S, Tsuruta N, Yamaguchi K et al. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics:real\u2043world data from 18 Japanese facilities [J]. J Dermatol,2020,47(2):128\u201332. https:\/\/doi.org\/10.1111\/1346-8138.15156","DOI":"10.1111\/1346-8138.15156"},{"key":"1959_CR52","unstructured":"Deodhar A, Gottlieb AB, Boehncke WH et al. Efficacy and safety of Guselkumab in patients with active psoriatic arthritis: a randomised,double\u2043blind, placebo\u2043controlled, phase 2 study. [J]. Lancet,2018, 391(10136):2213\u201324. doi: 10. 1016\/S 0140 \u20436736\u0f0818\u0f0930952-8."},{"key":"1959_CR53","doi-asserted-by":"crossref","unstructured":"Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis [J]. J Eur Acad Dermatol Venereol, 2019,33(9):1676\u20431684,doi:1111\/jdv.15653.","DOI":"10.1111\/jdv.15653"},{"key":"1959_CR54","doi-asserted-by":"publisher","unstructured":"Reich K, Warren RB, Iversen L et al. Long \u2043 term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase\u2162 clinical trials(reSURFACE 1 and reSURFACE 2) through 148 weeks [J]. Br J Dermatol, 2020,182\u0f083\u0f09:605\u2043617. https:\/\/doi.org\/10.1111\/bjd.18232","DOI":"10.1111\/bjd.18232"},{"issue":"3","key":"1959_CR55","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16724","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Reich K, Papp KA, et al. Safety of Tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials [J]. Br J Dermatol. 2018;179(3):615\u201322. https:\/\/doi.org\/10.1111\/bjd.16724.","journal-title":"Br J Dermatol"},{"key":"1959_CR56","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394\u201310198\u2013","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis(IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial [J]. Lancet. 2019;394\u201310198\u2013:576\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3.","journal-title":"Lancet"},{"issue":"7","key":"1959_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","volume":"15","author":"G Murphy","year":"2019","unstructured":"Murphy G. IsenbergDA. New therapies for systemic lupus erythematosus - past imperfect, futuretense. Nat Rev Rheumatol. 2019;15(7):403\u201312.","journal-title":"Nat Rev Rheumatol"},{"key":"1959_CR58","doi-asserted-by":"crossref","unstructured":"Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection[J]. Expert Rev Clin Immunol 2020,16(5):527\u201338.","DOI":"10.1080\/1744666X.2020.1763793"},{"key":"1959_CR59","doi-asserted-by":"crossref","unstructured":"Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with Belimumab in the treatment of SLE patients[J]. Rheum Dis Clin North Am 2014,40(3):507\u201317, viii.","DOI":"10.1016\/j.rdc.2014.04.007"},{"key":"1959_CR60","unstructured":"Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy [J]. Int J Health Sci(Qassim), 201711\u0f082\u0f09: 41\u201344."},{"issue":"10","key":"1959_CR61","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/rheumatology\/keg354","volume":"42","author":"G Cambridge","year":"2003","unstructured":"Cambridge G, et al. B-cell depletion in rheumatoid arthritis: a review of the evidence. Rheumatology (Oxford). 2003;42(10):1197\u2013204.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1959_CR62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.12816\/0046449","volume":"11","author":"A Alkadi","year":"2017","unstructured":"Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci. 2017;11(2):41\u20134. https:\/\/doi.org\/10.12816\/0046449.","journal-title":"Int J Health Sci"},{"key":"1959_CR63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and Anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25\u201332.","journal-title":"Ann Rheum Dis"},{"key":"1959_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","volume":"2","author":"MD Cohen","year":"2015","unstructured":"Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Therapy. 2015;2:99\u2013111.","journal-title":"Rheumatol Therapy"},{"key":"1959_CR65","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1959_CR66","doi-asserted-by":"publisher","first-page":"26762","DOI":"10.1074\/jbc.271.43.26762","volume":"271","author":"JL Greene","year":"1996","unstructured":"Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, Linsley PS. Covalent dimerization of CD28\/CTLA-4 and oligomerization of CD80\/CD86 regulate T cell costimulatory Interactions *. J Biol Chem. 1996;271:26762\u201371.","journal-title":"J Biol Chem"},{"key":"1959_CR67","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1742-7843.2009.00375.x","volume":"104","author":"R Korhonen","year":"2009","unstructured":"Korhonen R, Moilanen E. Abatacept, a novel CD80\/86\u2013CD28 T cell Co-stimulation Modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104:276\u201384.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"1959_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/acr.23824","volume":"72","author":"SK Chen","year":"2020","unstructured":"Chen SK, Liao KP,Liu J, et al. Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: A propensity Score-Matched cohort Study[J]. Arthritis Care Res (Hoboken). 2020;72(1):9\u201317.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1959_CR69","doi-asserted-by":"crossref","unstructured":"Gr\u00f8n KL. Glintborg B,N\u00f8rgaard M,Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab;an observational cohort study[J].Rheumatology (Oxford),2020,59(8):1949\u201356.","DOI":"10.1093\/rheumatology\/kez530"},{"issue":"8","key":"1959_CR70","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"JM Kremer","year":"2005","unstructured":"Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib,double-blind,randomized,placebo-controlled trial[J]. Arthritis Rheum. 2005;52(8):2263\u201371.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1959_CR71","first-page":"553","volume":"32","author":"R Westhovens","year":"2014","unstructured":"Westhovens R, Kremer JM,Emery P, et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study[J]. Clin Exp Rheumatol. 2014;32(4):553\u201362.","journal-title":"Clin Exp Rheumatol"},{"key":"1959_CR72","doi-asserted-by":"crossref","unstructured":"Winthrop KL, Park S-H, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y. Kwok,K.,Lukic,T.,Mortensen,E.,Ponce de Leon,D.,Riese,R.,&Valdez,H.2016.Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis,756,1133\u20138.","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"1959_CR73","doi-asserted-by":"crossref","unstructured":"Maiga M, Lun S, Guo H, Winglee K, Ammerman NC. &Bishai,W.R.2012.Risk of tuberculosis reactivation with tofacitinibCP-690550. J Infect Dis,20511,1705\u20138.","DOI":"10.1093\/infdis\/jis269"},{"key":"1959_CR74","unstructured":"Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR. Reactivation of latent tuberculosis infection following initiation of Tofacitinib therapy for rheumatoid arthritis: A case report. Journal of Orthopaedic Reports; 2023."},{"key":"1959_CR75","doi-asserted-by":"publisher","unstructured":"lopez-romerop delatorrei. haladyje, Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis (j). annrheumdis. 2022 Feb 22: annrheumdis-2021-221323. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221323","DOI":"10.1136\/annrheumdis-2021-221323"},{"key":"1959_CR76","doi-asserted-by":"crossref","unstructured":"Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, &Winthrop KL. 2022.Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatmentfinal results from long-term extension study and integrated database.Annals of the Rheumatic Diseases,81,335\u2013343.","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"1959_CR77","doi-asserted-by":"publisher","first-page":"152120","DOI":"10.1016\/j.semarthrit.2022.152120","volume":"58","author":"K Winthrop","year":"2023","unstructured":"Winthrop K, Isaacs J, Calabrese L, et al. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review. Semin Arthritis Rheum. 2023;58:152120.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1959_CR78","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"Cantini F, Blandizzi C, Niccoli L, et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus kinases. Expert Opin Drug Saf. 2020;19(7):861\u201372.","journal-title":"Expert Opin Drug Saf"},{"key":"1959_CR79","unstructured":"Lloyd N, Martin D, Peter DODC. Tuberculosis-Sixth Edition.CRC, 2020:154."},{"issue":"3","key":"1959_CR80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177\u201384. https:\/\/doi.org\/10.7326\/0003-4819-149-3-200808050-00241.","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"1959_CR81","doi-asserted-by":"publisher","first-page":"S1120","DOI":"10.1093\/infdis\/jir410","volume":"204","author":"JZ Metcalfe","year":"2011","unstructured":"Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-\u03b3 release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011;204(Suppl 4):S1120\u20131129. https:\/\/doi.org\/10.1093\/infdis\/jir410.","journal-title":"J Infect Dis"},{"issue":"1","key":"1959_CR82","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12890-020-01274-9","volume":"20","author":"PH Wang","year":"2020","unstructured":"Wang PH, Lin CH, Chang TH, et al. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. BMC Pulm Med. 2020;20(1):232. https:\/\/doi.org\/10.1186\/s12890-020-01274-9.","journal-title":"BMC Pulm Med"},{"key":"1959_CR83","unstructured":"Expert Recommendation Group on Tuberculosis Prevention and Management in Tumour Necrosis Factor Antagonist Applications. Expert consensus on tuberculosis prevention and management in the application of tumour necrosis factor antagonists[J]. Chin J Rheumatol 2013(08):508\u201312."},{"issue":"12","key":"1959_CR84","first-page":"863","volume":"52","author":"Chinese Society of Dermatology and Venereology","year":"2019","unstructured":"Chinese Society of Dermatology and Venereology. Expert consensus on biologic therapy for psoriasis in China (2019)[J]. Chin J Dermatology. 2019;52(12):863\u201371.","journal-title":"Chin J Dermatology"},{"issue":"1","key":"1959_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National tuberculosis controllers association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"1959_CR86","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40506-017-0135-7","volume":"9","author":"P Tang","year":"2017","unstructured":"Tang P, Johnston J. Treatment of latent tuberculosis infection. Curr Treat Options Infect Dis. 2017;9(4):371\u20139. https:\/\/doi.org\/10.1007\/s40506-017-0135-7.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"2","key":"1959_CR87","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","volume":"55","author":"GJ Njie","year":"2018","unstructured":"Njie GJ, Morris SB, Woodruff RY, et al. Isoniazid-Rifapentine for latent tuberculosis infection: A systematic review and Meta-analysis. Am J Prev Med. 2018;55(2):244\u201352. https:\/\/doi.org\/10.1016\/j.amepre.2018.04.030.","journal-title":"Am J Prev Med"},{"issue":"6","key":"1959_CR88","doi-asserted-by":"publisher","first-page":"1802180","DOI":"10.1183\/13993003.02180-2018","volume":"52","author":"D Menzies","year":"2018","unstructured":"Menzies D, Trajman A. New short regimens for latent tuberculosis treatment:safety first! Eur Respir J. 2018;52(6):1802180. https:\/\/doi.org\/10.1183\/13993003.02180-2018.","journal-title":"Eur Respir J"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01959-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01959-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01959-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:01:19Z","timestamp":1769565679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01959-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1959"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01959-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"112"}}